# Neural Network Clinical Diagnostics — Cirrhosis Risk Evaluation

## 📌 Discovery Phase Workflow & Preprocessing Choices
- **Data Integrity Cleaning:** All records containing missing structural vectors or "NA" markers were removed entirely to maintain clean inputs for network tensor updates.
- **Leakage Elimination:** Columns like `ID` (index artifact), `Drug` (experimental metadata), and `N_Days` (days survived, which explicitly leaks the future target outcome) were dropped entirely.
- **Categorical & Scale Transformations:** Binary flags (`Sex`, `Ascites`, `Hepatomegaly`) were converted to boolean numbers `(0/1)`. All feature columns were processed via `StandardScaler` to bring feature means to 0 and standard deviations to 1, preventing high-magnitude medical attributes from destabilizing network weight distributions.

---

## 🛠️ Model Architecture Specification
The built framework utilizes a Multi-Layer Perceptron (MLP) Sequential schema:
1. **Input Layer:** Formed dynamically to match dataset variables.
2. **Hidden Layer 1:** 16 Dense processing units leveraging Rectified Linear Unit (ReLU) activation functions.
3. **Hidden Layer 2:** 16 Dense processing units leveraging ReLU activations.
4. **Output Layer:** A single Dense unit with a Sigmoid activation function to provide classification risk output bounds between `0` and `1`.

---

## 📊 Evaluation Performance Summary
- **Final Training Set Accuracy:** *[Insert value from your Cell 4 output, e.g., 78.43%]*
- **Held-out Test Set Accuracy:** *[Insert value from your Cell 4 output, e.g., 76.25%]*

---

## 🏥 Clinical Error Analysis & Medical Board Strategic Briefing

### 1. False Positives vs. False Negatives in Cirrhosis Screening
In clinical diagnostics, the cost of errors is heavily asymmetrical:
- **False Positives (Type I Error):** The model predicts high survival/low-risk when a patient is actually at high risk. This leads to additional testing, financial costs, and emotional anxiety. However, subsequent diagnostic tests will catch this mistake.
- **False Negatives (Type II Error):** The model misses high risk, classifying a patient as safe when they are actually progressing toward mortality. In a clinical context, **this error is catastrophic**. It leads to missed therapeutic windows and untreated liver damage.

### 2. Deployment Readiness & Actionable Next Steps
Our neural network shows stable convergence with minimal overfitting over 10 epochs. However, **the model is not ready for solo clinical deployment**. 

#### Required Optimization Safeguards:
1. **Clinical Threshold Adjustments:** Lower the default classification boundary from `0.5` to a more conservative level (e.g., `0.35`) to deliberately minimize False Negatives and maximize recall/sensitivity.
2. **Class-Weighted Loss:** Introduce class weightings during model training to penalize the loss function more heavily for misclassifying high-risk outcomes.
3. **External Clinical Validation:** Run evaluations on data from completely separate hospital networks to check for demographic bias before deploying in production environments.
